353 related articles for article (PubMed ID: 29914049)
1. Anticoagulant Activities of Indobufen, an Antiplatelet Drug.
Liu J; Xu D; Xia N; Hou K; Chen S; Wang Y; Li Y
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914049
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology studies with indobufen (K 3920): inhibitor of platelet aggregation.
Vinazzer H; Fuccella LM
J Clin Pharmacol; 1980; 20(5-6 Pt 1):316-25. PubMed ID: 7400367
[TBL] [Abstract][Full Text] [Related]
3. Coagulation Testing in the Core Laboratory.
Winter WE; Flax SD; Harris NS
Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
[TBL] [Abstract][Full Text] [Related]
4. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Hawes EM; Deal AM; Funk-Adcock D; Gosselin R; Jeanneret C; Cook AM; Taylor JM; Whinna HC; Winkler AM; Moll S
J Thromb Haemost; 2013 Aug; 11(8):1493-502. PubMed ID: 23718677
[TBL] [Abstract][Full Text] [Related]
5. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
[TBL] [Abstract][Full Text] [Related]
6. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
[TBL] [Abstract][Full Text] [Related]
8. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
10. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
Eerenberg ES; Kamphuisen PW; Sijpkens MK; Meijers JC; Buller HR; Levi M
Circulation; 2011 Oct; 124(14):1573-9. PubMed ID: 21900088
[TBL] [Abstract][Full Text] [Related]
11. Experimental study on anticoagulant and antiplatelet aggregation activity of a chemically sulfated marine polysaccharide YCP.
Han F; Yao W; Yang X; Liu X; Gao X
Int J Biol Macromol; 2005 Sep; 36(4):201-7. PubMed ID: 16102810
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulant, anti-aggregation and antithrombotic effects of a novel hexapeptide.
Long LH; Cao YX; Ma Z; Liu J
J Pharm Pharmacol; 2011 Nov; 63(11):1454-61. PubMed ID: 21988426
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and in Vitro and in Vivo Anticoagulant and Antiplatelet Activities of Amidino- and Non-Amidinobenzamides.
Lee SH; Lee W; Bae JS; Ma E
Molecules; 2016 May; 21(5):. PubMed ID: 27213328
[TBL] [Abstract][Full Text] [Related]
14. Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure.
Douketis JD; Wang G; Chan N; Eikelboom JW; Syed S; Barty R; Moffat KA; Spencer FA; Blostein M; Schulman S
J Thromb Haemost; 2016 Jan; 14(1):89-97. PubMed ID: 26512880
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
[TBL] [Abstract][Full Text] [Related]
16. [Monitoring of Oral Thrombin Inhibitor].
Matsuno K; Usami T; Hatuse M; Shimizu C
Rinsho Byori; 2014 Oct; 62(10):958-64. PubMed ID: 27526541
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulant activity of a sulfated Lachnum polysaccharide in mice with a state of hypercoagulability.
Du Z; Shi F; Liu D; Ye H; Surhio MM; Li J; Ye M
Bioorg Med Chem Lett; 2016 Nov; 26(22):5550-5556. PubMed ID: 27769624
[TBL] [Abstract][Full Text] [Related]
18. PT, aPTT, TT and the hemostatic safety threshold of dabigatran and rivaroxaban.
Ibrahim F; Calmette L; Layka A; Horellou MH; Mazoyer É; Gouin-Thibault I; Flaujac C
Ann Biol Clin (Paris); 2016 Aug; 74(4):457-64. PubMed ID: 27492699
[TBL] [Abstract][Full Text] [Related]
19. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
[TBL] [Abstract][Full Text] [Related]
20. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
